Evidence map›Paper›PMID 19513102›Full record

ArticlePLoS neglected tropical diseases2009

Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis.

Anandharaman Veerapathran, Gajalakshmi Dakshinamoorthy, Munirathinam Gnanasekar, Maryada Venkata Rami Reddy, Ramaswamy Kalyanasundaram

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Dose-Dependent Prophylactic Efficacy of Filarial Antigens Glutathione-S-Transferase and Abundant Larval Transcript-2 againstThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. In-vitro and in silico efficacy of isolated alkaloid compounds fromJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2019
    Article
  15. Article
  16. Article
  17. Characterization of TwoFrontiers in microbiology · 2018
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Anandharaman VeerapathranDepartment of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America.
Gajalakshmi Dakshinamoorthy
Munirathinam Gnanasekar
Maryada Venkata Rami Reddy
Ramaswamy Kalyanasundaram
Illinois College · USMahatma Gandhi Institute of Medical Sciences · INUniversity of Illinois Chicago, Rockford campus · US

Funding

MULTIVALENT VACCINE FOR LYMPHATIC FILARIASISR01AI064745 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KALYANASUNDARAM, RAMASWAMY · 2007 to 2010
$1.5M
MULTIVALENT VACCINE FOR LYMPHATIC FILARIASISR56AI064745 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI KALYANASUNDARAM, RAMASWAMY · 2006 to 2006
$310k
NIAID NIH HHS R01 AI064745NIAID NIH HHS R01AI064745NIAID NIH HHS R56 AI064745
6 · The paper itself

Abstract

backgroundLymphatic filarial parasites survive within the lymphatic vessels for years despite the complex immune environment surrounding them. Parasites possibly accomplish this by adopting various immunomodulatory strategies, which include release of glutathione-S-transferases (GSTs) that counteract the oxidative free radicals produced by the host. Since GSTs produced by parasites appear to be critical for the survival of parasites in the host, several studies evaluated the potential of parasite GSTs as vaccine candidates especially against schistosomiasis, fascioliasis and Seteria cervi. However, vaccine potential of GSTs of lymphatic filarial parasites has not been evaluated before. METHODS/PRINCIPAL

findingsIn the present study, the GST gene was cloned from the third stage larval (L3) cDNA libraries of Wuchereria bancrofti, and recombinant GST (WbGST) was expressed and purified. Serum samples from individuals living in an endemic area were analyzed for their reactivity with rWbGST. These findings showed that sera from endemic normal individuals (EN) carry significant levels of anti-WbGST IgG antibodies compared to subjects who are microfilaraemic (Mf) or show symptoms of clinical pathology (CP). Isotype analysis of the anti-WbGST IgG antibodies showed a predominance of IgG1 and IgG3 antibodies in EN individuals. Subsequent functional analysis of the rWbGST showed that the rWbGST protein retained the enzymatic activity of GST and the antibodies in EN sera could inhibit this enzymatic activity. Similar results were obtained when anti-rWbGST antibodies raised in mice were used in the neutralization assay. Brugia malayi GST and WbGST show significant sequence similarity. Therefore, to evaluate the vaccine potential of rWbGST, we used B. malayi L3 as challenge parasites. Vaccine potential of rWbGST was initially evaluated by confirming the role of human and mice WbGST antibodies in an antibody dependent cellular cytotoxicity (ADCC) assay. Subsequent vaccination studies in a jird model showed that approximately 61% protection could be achieved against a B. malayi L3 challenge infection in jirds immunized with rWbGST.

conclusionsResults of this study show that rWbGST is a potential vaccine candidate against lymphatic filariasis. Nearly 61% protection can be achieved against a B. malayi challenge infection in a jird model. The study also showed that the WbGST protein retained the enzymatic activity of GST and this enzymatic activity appears to be critical for the survival of the parasite in the host.

Indexed as

AnimalsAntigens, HelminthBrugia malayiCloning, MolecularElephantiasis, FilarialFemaleGerbillinaeGlutathione TransferaseHelminth ProteinsHumansMaleMiceMice, Inbred BALB CRecombinant ProteinsVaccinesVaccines, SubunitAntigens, HelminthGlutathione TransferaseHelminth ProteinsRecombinant ProteinsVaccinesVaccines, SubunitVaccines, Synthetic

Identifiers

PMID19513102
PMCPMC2685978
OpenAlexW2001935604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.